Close Menu

emergency use authorization

Bio-Rad's PCR-based test is designed to detect SARS-CoV-2 nucleic acid, while United Biomedical's test detects antibodies against the virus.

The company is also working in parallel on an at-home test that would be over the counter and return results within an hour.

The test has been authorized for use with individual respiratory specimens, as well as with pooled specimens containing up to five samples.

The system is based on GNA's proprietary pulsed control amplification technology, which uses short electrical pulses to drive rapid amplification cycles.

The SARS-CoV-2 test, which runs on Cepheid's GeneXpert systems, is to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as nasal swabs.

The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated. 

The Solana SARS-CoV-2 test can be run in batches of 11 samples, with minimum hands on time, no extraction, and results in approximately 25 minutes.

The US Food and Drug Administration granted an Emergency Use Authorization for Moderna's SARS-CoV-2 vaccine, the New York Times reports.

The PCR-based test is designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as anterior nasal swabs collected by a healthcare provider.

Genetworx and PacificDx's tests detect SARS-CoV-2 nucleic acid, while Hologic's test can also detect and differentiate SARS-CoV-2 and influenza A and B.


The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.